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by echocardiogrephy and the time constant of LV relaxation (Tau) was derived 
from the LV pressure to assess diastolic function in 94 consecutive patients 
with suspected cardiac disease. The sensitivity and specificity of optimal 
values of each papttde !or detecting abe l  LV function or LVH were: 
EF < 45% sensitiv~: BNP (83%) > C-ANP (79%) > N-ANP (67%) 
specific~y: BNP (81%) > C-ANP (67%) > N-ANP (63%) 
Tau > 55 ms sensitivity; BNP (85%) > N-ANP (70%) > C-ANP (60%) 
specificity: BNP t74%) :- C-ANP (65%) > N-ANP {81%) 
LV mass index > 120 g/m 2 sensitivity: BNP (81%) > N-ANP (73%) > C-ANP (69%) 
specificity: BNP (90%) :. N-ANP (79=/.) > C-ANP (67%) 
By recaiver-operator-charactadstic (ROC) analysis, BNP was significantly 
more sensitive and specific than C-ANP or N.ANP for dstecting abnormal 
ER Tau or LV mass index with an ROC value of 0.85, 0.8?,, and 0.91 respac- 
tive~y. Sensitivity for detecting abnormal LV structure or function employing 
a "natfluretic peptido penal ~ with an abnormal ~NP orC-ANP or N-ANP ax- 
ceeded that of BNP alone and was for EF < 4S% (96%), Tau < 55 ms (90%) 
and LV mass index > 120 g/m 2 (06%). Conclusions:BNP is the single best 
test to detect abnormal systolic and diastolic function and LVH in patients 
with suspected cardiac disease. A "natriuretic peptide panel" has very high 
sensitivity and may be a useful screening test in some populations. 
4:15 
~ Attenuation B.type Peptt=de (BNP) of Natrluretic 
Secreted From an Infarcted Segment Remssnts the 
Process of  Left Vantricular Remodeling After 
Myocardial Infarction 
Atsusht Hirayama, Fuminobu lshikura, Neeyu~ Misaki, Hisakasu Fuji, 
Takayoshi Adechi, Yashuhlko Seksta, Kazuhisa Kodama, Osaka Police 
Hospital, Osaka, Japan 
As B-type natduratic peptide (BNP) is known tO be a marker for ventdcu- 
lar hypertrophy and/or dilatation, its measurement at the infarcted segment 
might be useful to evaluate infarct expansion after the onset of myocardial 
infarction (M1). Seventy five patients of first antedor MI without any car- 
diac event since their first attack were subjected to cardiac catheterization 
performed 18 ± 15 months (range 1 to 45 months) after the onset of MI. 
Hemodynamic parameters, left ventdcular (LV) volumes and function on LV 
graphy and plasma BNP concentration (pg/ml) of aortic root (Ao) and anterior 
intervantdcular vein (AIV) were measured by radioimmuncessay. The differ- 
once of plasma BNP concentration between AIV and Aa {AIV-Ao), which 
reflect BNP secreted from the infarct segment, had significant correlations 
with EDVI (r = 0.67, p = 0.001), ESVI (r = 0,65, p = 0.001), EF (r = 0.71, p = 
0.001), LVEDP (r = 0.53, p = 0.003), and the duration from the onset of MI to 
the cardiac catheterization (r= -0.75, p = 0.001). By multivariate analysis, 
however, EDVI (p = 0.003) and the duration from the onset of MI (p = 0.0021 )
among the variables were picked up as significant factors determining the 
plasma concentration of BNP at AIV-Ao. These results indicated that BNP 
released from the infarcted segment is enhanced by the ventdcular dilatation 
and attenuated in the course of time after ML These results suggested the 
secretion of BNP at the infarcted segment w~c stimulated by the infarct ex- 
pansion at the eady pedod after MI but decrJased with the accomplishment 
of expansion dudng the late period. 
In conclusion, BNP secreted from the infarct segment represent he pro* 
cess of LV remodeling after MI. 
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1723-3 ~ Repetitive Bolus Administration of Brain Natriuratlc 
Peptlde Reduces Cardiac Filling Pressures in 
Human Heart Failure 
Robert J, Cody, for the Natrecor hBNP Multicenter Bolus Trial. Ohio State 
University, Columbus, Ohio 
Endogenous natduretic poptides (NP) produce vesodilallon, in response to 
the myocardial remodeling of congestive heart failure (CHF). individual NP 
sequences of single gone origin, confer distinct cardiovascular character- 
istics. In this multicenter trial, we evaluated the effect of repetitive bolus 
administration of brain nstriuretic peptide (hBNP) in patients (pts) with CHF, 
during hemodynamic evaluation. 28 of 29 pts were NYHA II1 or IV, and all 
had EF < 30%. hBNP was given as 5 #g Q4H (7 pts), 10 p.g Q4H (6 
pts), 10 #g Q6H (6 pts), with placebo groups for Q4H (6 tots) and QaH 
(4 pts) tnten/ais. For each treatment inten~i, pts received repetitive doses 
over 24 hrs. Placebo groups were pooled for statistical analysis, considering 
betwaen4wlthin-group differences, and dosage hierarchy, p < 0.05(') being 
significant. Pulmonary wedge (PWP) and dght atrial (RAP) pressures: 
PWp (mmH9) 
Baseline 
hBNP + 0.5 hrs 
hBNP + 1 hr8 
hBNP + 2 hm 
RAP (mmHg) 
Basins 
hBNP + 0,S hrS 
hBNP + 1 hrs 
hBNP ÷ 2 hrs 
Placebo 5EgQ4H ............. !0/~g,Q4H 10/~g Q6 H 
27=7 2S±6 ~±6 27~5 
26:~9 ta~:P 19:1:8 • 12:EP 
27±8 1S±6* 20~7" 13:~6" 
26:b5 18±8' 21 ~-9 ~ 16 d:6" 
15-;-8 13±8 12~4 12-1-7 
15±7 10~8" 84-p 7:~5" 
16±7 9±9" 8±6 '~ 6±5" 
14d:a 10~8" 7 -;- 4'* 7:~5- 
At the common time point of 12 hours, PWP (15 4. 5) and RAP (4 :t: 
5,) were p < 0,05 for the 10 #g Q4H interval, With the final bolus In each 
group, persistent response of PWP and RAP indicated no tachyphylaxis. 
Changes in cardiac index and system~ resistance were concordant, canals. 
tent with vasedilation. In human CHF, exogenous hBNP improves cardiac 
filling pressures in the setting of vasodilation, sugge -3ting preserved hamody- 
namic responsiveness of the "type A" NP re,~ptor, wl~tle reducing the atdai 
tension stimulus for endogenous NP release. 
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Exhaled Nitric Oxide as a Measure of Response to 
Therapy in Patients With Heart Failure 
Joshua M. Hare, Anthony R Massaro, Jeffrey M, Drezen, Wilson S. Colucoi. 
Bn'gham and Women's Hospital, Boston, MA 
Endogenous nitric oxide (NO) can be detected in exhaled air and increases 
with exercise and L-arginine administration, possibly reflecting vascular e- 
lease, We hypothesized that exhaled NO would be elevated in patients with 
heart failure (HF) as a compensatory cimulatory mechanism, and would de. 
crease as hemodynamtcs improved with vasedilator and diuretic therapy. 
Chemilumineeanca was used to measure mean mixed expil~l NO content 
of a vital capacity breath in patients with HF (n = 5) and matched controls (n 
= 5) dudng inhalation of NO-free air. Exhaled NO was higher in HF than in 
controls (8.4 :E 3.5 vs. 6.5 :t: 2.4 ppb, p < 0,04). Serial measurements were 
made over of period of therapy (7,3 4- 6 dayS) with sodium nitroprusstde 
(SNP) and diuresis dudng monitoring of pulmonary artedal pressures and 
cardlec output in 7 additional patients with HF breathing room air. 
Pro-therapy SNP for 2 hrs .  Post-therapy 
NO (ppb) 20.4 ~: 6.2 22.8 :b 4.6 11.2 "~ 1.2' 
PVR (dyne-sec-cm-5) 356 ~- 47 287 ± 63 147 ~ 32" 
co (U~n) 3 ~: 0.3 4.64 =~ 0.9 4.8 ± 0.3t" 
PCWP (mmHg) 31 ~: 3 27 :E 2 21 :E 71" 
*p < 0,05 vs. baseline and SNP, tp < 0.01 vs. baseline 
HF therapy improves hemedynamics and is as,~oclated with reductions 
in exhaled NO concentrations. Thus, elevations in exhaled NO may reflect 
a compensatory cimulatory mechanism in HI=, and exhaled NO may be an 
easily obtainable and quantifiable measure of clinical response to therapy in 
HR 
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~ Medulatlon of Tumor Necrosis Factor o~ in 
Advanced Heart Failure With Cachexla Is 
Associated Wilh Anabol lc Effects 
Richard V. Mtisni, Stefan Endres, Mandeep R, Mehra, Julia Cook, 
Andreas Eigler0 Frank W. Smart, Cad J. Lavla, Joseph R Murgo, Hector 
O. Vanfura. Ochsner Clinic, New Orleans. LA 
Tumor Necrosis Factor (TNF~) has catabolic effects which produce cachexia 
in laboratory animals and humans. Indeed, patients with advanced heart 
failure (aHF) who demonstrate elevated levels of TNFc< often suffer from 
cachexla, a finding characterized by reduced body ~'at. The purpose of this 
double blind, randomized, placebo-controlled study was to evaluate the im- 
pact of modulation of TNF= synthesis on alterations in body fat Indlces 
using n-3 fatty acids. 14 patients with aHF were randomly allocated to ac- 
tive treatment (n.3 fatty adds, 6.4 gins/d; n = 7) vs. t~ocaloric placebo (n 
= 7). TNF= production at baseline and after 18 weeks was assessed using 
lipopolysaccadde monocyte stimulation. 
t.TNF~ synthesis 4% Body Fat 
n-3 Fatty Acids -59% +9.5% 
Placebo +44% -4.2=/=, 
Regression analysis revealed that &TNF~ was inversely and significantly 
correlated with z~% body fat (r value = 0.60, p = 0.02). Conclusions: 1) 
N-3 fatty acid supplementation in aHF results in significant reductions in 
